Ann: Appendix 4D and Half Yearly Report, page-250

I believe the stock got way ahead of itself early in the piece with the sudden rise driven by the heard mentality and day traders jumping on board a stock that was making daily highs early in the piece after the initial trial results were released to the market. There was always going to be a correction in the share price as the process to approval was never going to happen overnight and I believe we are still some way off from getting this and wont be surprised if the FDA request some additional testing be carried out over an above what has already been done and what this is wont be known until after the initial FDA engagement meeting. On top of this a number of initial cornerstone investors have made some good coin since the listing and are probably happy to cash out and possibly return back to the stock once the FDA pathway has more clarity. We know the product works and to date from what has been broadcast, the side effects seem to be minimal compared to the tablet form, so I am comfortable with my investment but like everyone else I would always like things to move quicker than they currently are but I guess that seems to be the norm with BIO stocks so it seems.